• Something wrong with this record ?

European dermatology forum: Updated guidelines on the use of extracorporeal photopheresis 2020 - Part 2

R. Knobler, P. Arenberger, A. Arun, C. Assaf, M. Bagot, G. Berlin, A. Bohbot, P. Calzavara-Pinton, F. Child, A. Cho, LE. French, AR. Gennery, R. Gniadecki, HPM. Gollnick, E. Guenova, P. Jaksch, C. Jantschitsch, C. Klemke, J. Ludvigsson, E....

. 2021 ; 35 (1) : 27-49. [pub] 20200922

Language English Country Great Britain

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc21019559

BACKGROUND: Following the first investigational study on the use of extracorporeal photopheresis for the treatment of cutaneous T-cell lymphoma published in 1983, this technology has received continued use and further recognition for additional earlier as well as refractory forms. After the publication of the first guidelines for this technology in the JEADV in 2014, this technology has maintained additional promise in the treatment of other severe and refractory conditions in a multidisciplinary setting. It has confirmed recognition in well-known documented conditions such as graft-vs.-host disease after allogeneic bone marrow transplantation, systemic sclerosis, solid organ transplant rejection including lung, heart and liver and to a lesser extent inflammatory bowel disease. MATERIALS AND METHODS: In order to further provide recognized expert practical guidelines for the use of this technology for all indications, the European Dermatology Forum (EDF) again proceeded to address these questions in the hands of the recognized experts within and outside the field of dermatology. This was done using the recognized and approved guidelines of EDF for this task. All authors had the opportunity to review each contribution as it was added. RESULTS AND CONCLUSION: These updated 2020 guidelines provide at present the most comprehensive available expert recommendations for the use of extracorporeal photopheresis based on the available published literature and expert consensus opinion. The guidelines were divided into two parts: PART I covers Cutaneous T-cell lymphoma, chronic graft-vs.-host disease and acute graft-vs.-host disease, while PART II will cover scleroderma, solid organ transplantation, Crohn's disease, use of ECP in paediatric patients, atopic dermatitis, type 1 diabetes, pemphigus, epidermolysis bullosa acquisita and erosive oral lichen planus.

3rd Faculty of Medicine Charles University Prague Czech Republic

Crown Princess Victoria Children's Hospital and Division of Pediatrics Department of Biomedical and Clinical Sciences University Hospital Linköping University Linköping Sweden

Department Dermatology and Venereology Otto von Guericke University Magdeburg Germany

Department of Cardiac Surgery Medical University of Vienna Vienna Austria

Department of Clinical Immunology and Transfusion Medicine Department of Biomedical and Clinical Sciences Linköping University Linköping Sweden

Department of Dermatology and Venerology Helios Klinikum Krefeld Krefeld Germany

Department of Dermatology Medical University of Graz Graz Austria

Department of Dermatology Medical University of Vienna Vienna Austria

Department of Dermatology University Clinics Schleswig Holstein Kiel Germany

Department of Dermatology University Hospital München Germany

Department of Thoracic Surgery Medical University Vienna Vienna Austria

Departments of Dermatology Venereology Allergology and Immunology Dessau Medical Center Brandenburg Medical School Theodor Fontane Dessau Germany

Dermatology Department University of Brescia Italy Brescia Italy

Division of Dermatology University of Alberta Edmonton Canada

Faculty of Biology and Medicine University of Lausanne and Department of Dermatology Lausanne University Hospital CHUV Lausanne Switzerland

FRCP St John's Institution of Dermatology Guy's and St Thomas' NHS Foundation Trust London United Kingdom

FRCPath The Rotherham NHA Foundation Trust Rotherham United Kingdom

Hautklinik Städtisches Klinikum Karlsruhe Karlsruhe Germany

Hospital Saint Louis Université de Paris Paris France

LKH Univ Klinikum Graz Division of Haematology Medical University of Graz Graz Austria

National and Kapodistrian University of Athens Athens Greece

Onco Hematology Department Hautepierre Hospital Strasbourg France

Translational and Clinical Research Institute Newcastle University Great North Children's Hospital Newcastle upon Tyne Newcastle University Newcastle upon Tyne United Kingdom

University Clinic for Dermatology Johannes Wesling Medical Centre UKRUB University of Bochum Minden Germany

University Hospital Birmingham Birmingham United Kingdom

Vanderbilt University Medical Center Department of Dermatology Nashville Tennessee USA

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21019559
003      
CZ-PrNML
005      
20210830101143.0
007      
ta
008      
210728s2021 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/jdv.16889 $2 doi
035    __
$a (PubMed)32964529
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Knobler, R $u Department of Dermatology, Medical University of Vienna, Vienna, Austria
245    10
$a European dermatology forum: Updated guidelines on the use of extracorporeal photopheresis 2020 - Part 2 / $c R. Knobler, P. Arenberger, A. Arun, C. Assaf, M. Bagot, G. Berlin, A. Bohbot, P. Calzavara-Pinton, F. Child, A. Cho, LE. French, AR. Gennery, R. Gniadecki, HPM. Gollnick, E. Guenova, P. Jaksch, C. Jantschitsch, C. Klemke, J. Ludvigsson, E. Papadavid, J. Scarisbrick, T. Schwarz, R. Stadler, P. Wolf, J. Zic, C. Zouboulis, A. Zuckermann, H. Greinix
520    9_
$a BACKGROUND: Following the first investigational study on the use of extracorporeal photopheresis for the treatment of cutaneous T-cell lymphoma published in 1983, this technology has received continued use and further recognition for additional earlier as well as refractory forms. After the publication of the first guidelines for this technology in the JEADV in 2014, this technology has maintained additional promise in the treatment of other severe and refractory conditions in a multidisciplinary setting. It has confirmed recognition in well-known documented conditions such as graft-vs.-host disease after allogeneic bone marrow transplantation, systemic sclerosis, solid organ transplant rejection including lung, heart and liver and to a lesser extent inflammatory bowel disease. MATERIALS AND METHODS: In order to further provide recognized expert practical guidelines for the use of this technology for all indications, the European Dermatology Forum (EDF) again proceeded to address these questions in the hands of the recognized experts within and outside the field of dermatology. This was done using the recognized and approved guidelines of EDF for this task. All authors had the opportunity to review each contribution as it was added. RESULTS AND CONCLUSION: These updated 2020 guidelines provide at present the most comprehensive available expert recommendations for the use of extracorporeal photopheresis based on the available published literature and expert consensus opinion. The guidelines were divided into two parts: PART I covers Cutaneous T-cell lymphoma, chronic graft-vs.-host disease and acute graft-vs.-host disease, while PART II will cover scleroderma, solid organ transplantation, Crohn's disease, use of ECP in paediatric patients, atopic dermatitis, type 1 diabetes, pemphigus, epidermolysis bullosa acquisita and erosive oral lichen planus.
650    _2
$a dítě $7 D002648
650    12
$a dermatologie $7 D003880
650    12
$a nemoc štěpu proti hostiteli $7 D006086
650    _2
$a lidé $7 D006801
650    12
$a kožní T-buněčný lymfom $x terapie $7 D016410
650    12
$a fotoferéza $7 D017893
650    12
$a nádory kůže $7 D012878
655    _2
$a časopisecké články $7 D016428
700    1_
$a Arenberger, P $u Third Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Arun, A $u FRCPath, The Rotherham NHA Foundation Trust, Rotherham, United Kingdom
700    1_
$a Assaf, C $u Department of Dermatology and Venerology, Helios Klinikum Krefeld, Krefeld, Germany
700    1_
$a Bagot, M $u Hospital Saint Louis, Université de Paris, Paris, France
700    1_
$a Berlin, G $u Department of Clinical Immunology and Transfusion Medicine, Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden
700    1_
$a Bohbot, A $u Onco-Hematology Department, Hautepierre Hospital, Strasbourg, France
700    1_
$a Calzavara-Pinton, P $u Dermatology Department, University of Brescia Italy, Brescia, Italy
700    1_
$a Child, F $u FRCP, St John's Institution of Dermatology, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom
700    1_
$a Cho, A $u Department of Dermatology, Medical University of Vienna, Vienna, Austria
700    1_
$a French, L E $u Department of Dermatology, University Hospital, München, Germany
700    1_
$a Gennery, A R $u Translational and Clinical Research Institute Newcastle University Great North Children's Hospital Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne, United Kingdom
700    1_
$a Gniadecki, R $u Division of Dermatology, University of Alberta, Edmonton, Canada
700    1_
$a Gollnick, H P M $u Department Dermatology & Venereology Otto-von-Guericke University, Magdeburg, Germany
700    1_
$a Guenova, E $u Faculty of Biology and Medicine, University of Lausanne and Department of Dermatology, Lausanne University Hospital CHUV, Lausanne, Switzerland
700    1_
$a Jaksch, P $u Department of Thoracic Surgery, Medical University Vienna, Vienna, Austria
700    1_
$a Jantschitsch, C $u Department of Dermatology, Medical University of Vienna, Vienna, Austria
700    1_
$a Klemke, C $u Hautklinik Städtisches Klinikum Karlsruhe, Karlsruhe, Germany
700    1_
$a Ludvigsson, J $u Crown Princess Victoria Children's Hospital and Division of Pediatrics, Department of Biomedical and Clinical Sciences, University Hospital, Linköping University, Linköping, Sweden
700    1_
$a Papadavid, E $u National and Kapodistrian University of Athens, Athens, Greece
700    1_
$a Scarisbrick, J $u University Hospital Birmingham, Birmingham, United Kingdom
700    1_
$a Schwarz, T $u Department of Dermatology, University Clinics Schleswig-Holstein, Kiel, Germany
700    1_
$a Stadler, R $u University Clinic for Dermatology Johannes Wesling Medical Centre, UKRUB, University of Bochum, Minden, Germany
700    1_
$a Wolf, P $u Department of Dermatology, Medical University of Graz, Graz, Austria
700    1_
$a Zic, J $u Vanderbilt University Medical Center Department of Dermatology, Nashville, Tennessee, USA
700    1_
$a Zouboulis, C $u Departments of Dermatology, Venereology, Allergology and Immunology, Dessau Medical Center, Brandenburg Medical School Theodor Fontane, Dessau, Germany
700    1_
$a Zuckermann, A $u Department of Cardiac Surgery, Medical University of Vienna, Vienna, Austria
700    1_
$a Greinix, H $u LKH-Univ. Klinikum Graz, Division of Haematology, Medical University of Graz, Graz, Austria
773    0_
$w MED00002983 $t Journal of the European Academy of Dermatology and Venereology : JEADV $x 1468-3083 $g Roč. 35, č. 1 (2021), s. 27-49
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32964529 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20210830101143 $b ABA008
999    __
$a ok $b bmc $g 1690400 $s 1140005
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 35 $c 1 $d 27-49 $e 20200922 $i 1468-3083 $m Journal of the European Academy of Dermatology and Venereology $n J Eur Acad Dermatol Venerol $x MED00002983
LZP    __
$a Pubmed-20210728

Find record

Citation metrics

Archiving options